Articles By Anuja Singh

Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal…

Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…

ByByAnuja Singh Jan 1, 2026
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and…

Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…

ByByAnuja Singh Jan 1, 2026
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?

Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…

ByByAnuja Singh Jan 1, 2026
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?

Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…

ByByAnuja Singh Jan 1, 2026
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma…

Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding its platform in…

ByByAnuja Singh Jan 1, 2026
Is Theremia Using AI to Unlock Next-Generation Immuno-Oncology Therapies and Advance Pharma Partnerships?

Strategic Overview Theremia is emerging as a pioneering AI-driven biotech focused on immune system modulation for oncology, integrating…

ByByAnuja Singh Jan 1, 2026
Image Not Found
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal…

Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…

ByByAnuja Singh Jan 1, 2026
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and…

Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…

ByByAnuja Singh Jan 1, 2026
Can ReviR’s AI-Powered RNA Modulation Platform Convert $50M+ in Funding into Scalable Genetic Medicines?

Executive Summary ReviR Therapeutics continues to establish itself as a leader in RNA-targeting small molecule drug discovery, advancing…

ByByAnuja Singh Jan 1, 2026
Can Ainnocence’s Causal AI Platform Redefine Drug Discovery Value as Pharma Expands AI Partnerships?

Strategic Overview Ainnocence is carving out a differentiated role in AI-driven drug discovery by emphasizing causal, mechanism-oriented artificial…

ByByAnuja Singh Jan 1, 2026
Can Standigm’s Knowledge-Graph AI Outperform AI Peers Like Exscientia and Insilico as Global Pharma…

Strategic Overview Standigm is emerging as a distinctive force in AI-driven drug discovery by grounding its platform in…

ByByAnuja Singh Jan 1, 2026
Is Theremia Using AI to Unlock Next-Generation Immuno-Oncology Therapies and Advance Pharma Partnerships?

Strategic Overview Theremia is emerging as a pioneering AI-driven biotech focused on immune system modulation for oncology, integrating…

ByByAnuja Singh Jan 1, 2026
Scroll to Top